Orchard Therapeutics Past Earnings Performance
Past criteria checks 0/6
Orchard Therapeutics has been growing earnings at an average annual rate of 12.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 57.1% per year.
Key information
12.3%
Earnings growth rate
63.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 57.1% |
| Return on equity | -90.9% |
| Net Margin | -333.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Orchard Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 22 | -73 | 44 | 0 |
| 30 Jun 23 | 21 | -85 | 44 | 0 |
| 31 Mar 23 | 18 | -124 | 47 | 0 |
| 31 Dec 22 | 23 | -151 | 49 | 0 |
| 30 Sep 22 | 16 | -179 | 51 | 0 |
| 30 Jun 22 | 12 | -168 | 53 | 0 |
| 31 Mar 22 | 7 | -154 | 53 | 0 |
| 31 Dec 21 | 2 | -145 | 54 | 0 |
| 30 Sep 21 | 1 | -142 | 57 | 0 |
| 30 Jun 21 | 2 | -126 | 57 | -50 |
| 31 Mar 21 | 3 | -137 | 58 | -25 |
| 31 Dec 20 | 3 | -152 | 61 | 0 |
| 30 Sep 20 | 3 | -164 | 63 | 31 |
| 30 Jun 20 | 3 | -180 | 65 | 109 |
| 31 Mar 20 | 3 | -183 | 63 | 125 |
| 31 Dec 19 | 3 | -163 | 57 | 117 |
| 30 Sep 19 | 3 | -143 | 51 | 237 |
| 30 Jun 19 | 2 | -140 | 44 | 103 |
| 31 Mar 19 | 2 | -246 | 38 | 214 |
| 31 Dec 18 | 2 | -230 | 31 | 205 |
| 30 Sep 18 | 1 | -219 | 21 | 65 |
| 30 Jun 18 | 0 | -198 | 16 | 182 |
| 31 Mar 18 | 0 | -48 | 9 | 36 |
| 31 Dec 17 | 0 | -40 | 6 | 33 |
Quality Earnings: OT10 is currently unprofitable.
Growing Profit Margin: OT10 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OT10 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare OT10's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OT10 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: OT10 has a negative Return on Equity (-90.86%), as it is currently unprofitable.